Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on H. pylori Infection in Mongolian gerbils

Guo, Le; Yang, Hua; Tang, Feng; Yin, Runsheng; Liu, Hongpeng; Gong, Xiaochun; Wei, Jun; Zhang, Ying; Xu, Guofeng; Liu, Kunmei

doi:10.3389/fcimb.2017.00349

Cited by 53 publications

(48 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stomach colonization was reduced by 3‐4‐log orders in animals treated with both CWAE vaccines compared to infected gerbils and by 1‐log versus gerbils vaccinated with either a univalent epitope‐based vaccine against H. pylori urease or a urease vaccine . Antibody response and gastritis were also improved with the CWAE vaccine . Thus, this multivalent epitope‐based vaccine may be a promising candidate to control H. pylori infection.…”

Section: Vaccinesmentioning

confidence: 94%

“…These proteins were administered per os together with aluminum hydroxide adjuvant or polysaccharide adjuvant in gerbils infected with H. pylori SS1, 6 weeks after infection; H. pylori burden was assessed 5 weeks after vaccination. Stomach colonization was reduced by 3‐4‐log orders in animals treated with both CWAE vaccines compared to infected gerbils and by 1‐log versus gerbils vaccinated with either a univalent epitope‐based vaccine against H. pylori urease or a urease vaccine . Antibody response and gastritis were also improved with the CWAE vaccine .…”

Section: Vaccinesmentioning

confidence: 97%

“…36 41 Antibody response and gastritis were also improved with the CWAE vaccine. 40 Thus, this multivalent epitope-based vaccine may be a promising candidate to control H. pylori infection.…”

Section: The Proinflammatory Response Characterized By the Th1 Andmentioning

confidence: 99%

“…They cloned in Escherichia coli two plasmids containing CD4 + Th cell and B cell epitopes in antigenic H. pylori proteins predicted by T Cell Epitope Prediction Tools and B Cell Epitope Prediction Tools. The first harbored (a) two molecular adjuvants (mucosal adjuvant cholera toxin B subunit and Th1‐type adjuvant), (b) tandem copies of the selected B and Th cell epitopes (UreA 27‐53 , UreA 183‐203 , HpaA 132‐141 , and heat shock protein 60 189‐203 ), and (c) epitope‐rich regions UreB 158‐251 containing four known Th or B cell epitopes and UreB 321‐385 containing three Th or B cell epitopes . The second was composed of (a) the mucosal adjuvant cholera toxin B subunit, (b) Th and B‐cell epitopes (UreA 27‐90 , UreA 183‐225 , UreB 327‐385 , membrane‐associated lipoprotein Lpp20 58‐97 , HpaA 52‐194 , and CagL 21‐139 ), and (c) an Lpp20 mimotope .…”

Section: Vaccinesmentioning

confidence: 99%

See 3 more Smart Citations

Helicobacter: Inflammation, immunology, and vaccines

et al. 2018

View full text Add to dashboard Cite

Helicobacter pylori infection induces a chronic gastric inflammation which can lead to gastric ulcers and cancer. The mucosal immune response to H. pylori is first initiated by the activation of gastric epithelial cells that respond to numerous bacterial factors, such as the cytotoxin-associated gene A or the lipopolysaccharide intermediate heptose-1,7-bisphosphate. The response of these cells is orchestrated by different receptors including the intracellular nucleotide-binding oligomerization domain-containing protein 1 or the extracellular epidermal growth factor receptor. This nonspecific response leads to recruitment and activation of various myeloid (macrophages and dendritic cells) and T cells (T helper-17 and mucosal-associated invariant T cells), which magnify and maintain inflammation. In this review, we summarize the major advances made in the past year regarding the induction, the regulation, and the role of the innate and adaptive immune responses to H. pylori infection. We also recapitulate efforts that have been made to develop efficient vaccine strategies.

show abstract

Section: Vaccinesmentioning

confidence: 94%

Section: Vaccinesmentioning

confidence: 97%

Section: The Proinflammatory Response Characterized By the Th1 Andmentioning

confidence: 99%

Section: Vaccinesmentioning

confidence: 99%

See 2 more Smart Citations

Helicobacter: Inflammation, immunology, and vaccines

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A chimeric vaccine, consisting of UreA and UreB, was constructed and expressed in E. coli. The recombinant protein was purified and used for intragastric vaccination of Mongolian gerbils [127] and C57BL/6 mice [128], which showed partial inhibition of H. pylori infection. Regarding the limited success of intragastric vaccination, some researchers have focused on new platforms for an oral administration of the vaccines, including a vaccine expressed in Lactococcus lactis NZ9000, and the spores of Bacillus subtilis.…”

Section: References Year Routementioning

confidence: 99%

Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination

et al. 2018

View full text Add to dashboard Cite

Helicobacter pylori affect around 50% of the population worldwide. More importantly, the gastric infection induced by this bacterium is deemed to be associated with the progression of distal gastric carcinoma and gastric mucosal lymphoma in the human. H. pylori infection and its prevalent genotype significantly differ across various geographical regions. Based on numerous virulence factors, H. pylori can target different cellular proteins to modulate the variety of inflammatory responses and initiate numerous "hits" on the gastric mucosa. Such reactions lead to serious complications, including gastritis and peptic ulceration, gastric cancer and gastric mucosa-associated lymphoid structure lymphoma. Therefore, H. pylori have been considered as the type I carcinogen by the Global Firm for Research on Cancer. During the two past decades, different reports revealed that H. pylori possess oncogenic potentials in the gastric mucosa through a complicated interplay between the bacterial factors, various facets, and the environmental factors. Accordingly, numerous signaling pathways could be triggered in the development of gastrointestinal diseases (e.g., gastric cancer). Therefore, the main strategy for the treatment of gastric cancer is controlling the disease far before its onset using preventive/curative vaccination. Increasing the efficiency of vaccines may be achieved by new trials of vaccine modalities, which is used to optimize the cellular immunity. Taken all, H. pylori infection may impose severe complications, for resolving of which extensive researches are essential in terms of immune responses to H. pylori. We envision that H. pylori-mediated diseases can be controlled by advanced vaccines and immunotherapies.

show abstract

Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection

Eslami

Yousefi

Ghasemian

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a resident bacterium in the stomach that accounts for 75% cases of gastric cancer. In this review, we comprehensively studied published papers on H. pylori vaccines using Google Scholar and NCBI databases to gather information about vaccines against H. pylori. Considering the pivotal roles of the enzyme urease (in production of NH 3 and neutralization of the acidic medium of the stomach), cytotoxinassociated gene A, and vacuolating cytotoxin A proteins in H. pylori infection, they could be the best candidates for the construction of recombinant vaccines. The outer membrane porins (Hop), blood group antigen-binding adhesin (BabA), sialic acid-binding adhesin (SabA), and outer inflammatory protein A, play significant roles in binding of bacterium to human gastric tissues, and because binding is the first step in bacterial fixation and colonization, these antigens also can be considered as suitable candidates for designing vaccines. Likely, other significant bacterial antigens, such as NapA (chemotactic factor for recruitment of human neutrophils and monocytes to the site of infection), duodenal ulcer promoting protein A (to promote duodenal ulcer), and Hsp60 (as a molecular chaperon for activation of urease enzyme), can be used in the construction of subunit vaccines. New vaccines in use currently, such as DNA vaccines and subunit vaccines, can efficiently replace the dead and attenuated vaccines. Nonetheless, the results show that urease enzyme is most used compared with bacterial components in the designing and construction of recombinant vaccines. The BabA and SabA antigens belong to the outer membrane porins family in H. pylori and are required for binding and fixation of the bacterium to the human gastric tissues. K E Y W O R D SCagA, Helicobacter pylori, recombinant vaccine, urease, VacA

show abstract

Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on H. pylori Infection in Mongolian gerbils

Cited by 53 publications

References 49 publications

Helicobacter: Inflammation, immunology, and vaccines

Helicobacter: Inflammation, immunology, and vaccines

Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination

Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection

Contact Info

Product

Resources

About